CoChat

Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine

Open access
Novelli, Giuseppe, Spitalieri, Paola, Murdocca, Michela, Centanini, Eleonora, Sangiuolo, Federica · 2023 · Frontiers in Cell and Developmental Biology

The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.

Abstract

During the last decades, hiPSC-derived organoids have been extensively studied and used as in vitro models for several applications among which research studies. They can be considered as organ and tissue prototypes, especially for those difficult to obtain. Moreover, several diseases can be accurately modeled and studied. Hence, patient-derived organoids (PDOs) can be used to predict individual drug responses, thus paving the way toward personalized medicine. Lastly, by applying tissue engineering and 3D printing techniques, organoids could be used in the future to replace or regenerate damaged tissue. In this review, we will focus on hiPSC-derived 3D cultures and their ability to model human diseases with an in-depth analysis of gene editing applications, as well as tumor models. Furthermore, we will highlight the state-of-the-art of organoid facilities that around the world offer know-how and services. This is an increasing trend that shed the light on the need of bridging the publicand the private sector. Hence, in the context of drug discovery, Organoid Factories can offer biobanks of validated 3D organoid models that can be used in collaboration with pharmaceutical companies to speed up the drug screening process. Finally, we will discuss the limitations and the future development that will lead hiPSC-derived technology from bench to bedside, toward personalized medicine, such as maturity, organoid interconnections, costs, reproducibility and standardization, and ethics. hiPSC-derived organoid technology is now passing from a proof-of-principle to real applications in the clinic, also thanks to the applicability of techniques, such as CRISPR/Cas9 genome editing system, material engineering for the scaffolds, or microfluidic systems. The benefits will have a crucial role in the advance of both basic biological and translational research, particularly in the pharmacological field and drug development. In fact, in the near future, 3D organoids will guide the clinical decision-making process, having validated patient-specific drug screening platforms. This is particularly important in the context of rare genetic diseases or when testing cancer treatments that could in principle have severe side effects. Therefore, this technology has enabled the advancement of personalized medicine in a way never seen before.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcell.2022.1059579

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Figure 1: hiPSCs offer a unique patient-specific model to study rare disease: hiPSCs can be differentiated into organ-specific cells and assembled into organoids comprised of organ-specific tissue. Organoids factory offers the unique opportunity to create platforms for drug screening, regenerative medicine, toxicity profiling and biobanking, accelerating clinical decision-making process or the discovery of new therapies.
FIGURE 1 Figure 1: hiPSCs offer a unique patient-specific model to study rare disease: hiPSCs can be differentiated into organ-specific cells and assembled into organoids comprised of organ-specific tissue. Organoids factory offers the unique opportunity to create platforms for drug screening, regenerative medicine, toxicity profiling and biobanking, accelerating clinical decision-making process or the discovery of new therapies.CC BY · PubMed Central
FIGURE 2 Schematic representation of hiPSCs derivation and their gene editing with the CRISPR-Cas9 system. CRISPR-Cas9 technology is applied to cultures of hiPSCsthat can be further differentiated and cultivated in 2D or 3D organoids. Isogenic hiPSCs or organoids can be obtained from healthy individuals through genetic mutations (left) or from patients through gene corrections (right). Created with BioRender.com.
FIGURE 2 Schematic representation of hiPSCs derivation and their gene editing with the CRISPR-Cas9 system. CRISPR-Cas9 technology is applied to cultures of hiPSCsthat can be further differentiated and cultivated in 2D or 3D organoids. Isogenic hiPSCs or organoids can be obtained from healthy individuals through genetic mutations (left) or from patients through gene corrections (right). Created with BioRender.com.CC BY · PubMed Central
FIGURE 3 Derivations and potential applications of patient-derived tumor organoids (PDOs). PDOs can be used in the clinic as a drug screening platform and to guide personalized immunotherapy. Similarly, PDOs are a useful tool for fundamental research. Created with BioRender.com.
FIGURE 3 Derivations and potential applications of patient-derived tumor organoids (PDOs). PDOs can be used in the clinic as a drug screening platform and to guide personalized immunotherapy. Similarly, PDOs are a useful tool for fundamental research. Created with BioRender.com.CC BY · PubMed Central
FIGURE 4 World distribution map of the organoid factories in academia and in the private sectorTables.
FIGURE 4 World distribution map of the organoid factories in academia and in the private sectorTables.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. Harford, 2022, RSV-induced changes in a 3-dimensional organoid model of human fetal lungs, PLoS One, 17, e0265094, 10.1371/journal.pone.0265094 · DOI
  2. 2022, Snyder institute for chronic diseases
  3. 2022, Karolinska institutet stem cell organoid
  4. Zhou, Patient-derived organoids in precision medicine: Drug screening, organoid-on-a-chip and living organoid biobank, Front. Oncol., 11, 5625, 10.3389/fonc.2021.762184 · DOI · Paper page

Cited by

See all 43

Metadata

Authors
Novelli, G., Spitalieri, P., Murdocca, M., Centanini, E., & Sangiuolo, F.
Affiliations
  • University of Rome Tor Vergata (IT)
  • University of Calabria (IT)
Corresponding author
Novelli, Giuseppe
Venue
Frontiers in Cell and Developmental Biology
Published
2023-01-09
Volume
10
Pages
1059579-1059579
ISSN
2296-634X (ISSN-L)
OpenAlex
W4313948710
Cited by
43
References
126
Citations by year
2026: 9 · 2025: 11 · 2024: 16 · 2023: 7
FWCI
1.13
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
human induced pluripotent stem cells, organoids, patient-derived organoids, precision medicine, disease modeling, drug screening, personalized medicine, CRISPR/Cas9 genome editing, tumor models, organoid biobank, 3D organoid culture, tissue engineering, 3D printing, microfluidics, scaffolds, rare genetic disorders, drug repurposing, translational research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.